Table 1.
Characteristics of T2D patients on Jan 1, 2017 as frequencies (proportions) unless otherwise stated
| All patients | Used only metformin in 2016 | Used metformin and other OAD in 2016 | Used only other diabetes medications than insulin or metformin in 2016 | Used insulin and OAD (inc. metformin) in 2016 | Used only insulin in 2016 | |
|---|---|---|---|---|---|---|
| n (%) | 8143 (100) | 2271 (27.9) | 1430 (17.6) | 726 (8.9) | 2112 (25.9) | 577 (7.1) |
| Mean age, years (SD) | 68.1 (11.3) | 69.5 (10.7) | 68.0 (10.8) | 71.8 (10.8) | 69.4 (10.9) | 74.0 (11.9) |
| < 75 years old | 5203 (63.9) | 1519 (66.9) | 1040 (72.7) | 407 (56.1) | 1423 (67.4) | 281 (48.7) |
| ≥75 years old | 2940 (36.1) | 752 (33.1) | 390 (27.3) | 319 (43.9) | 689 (32.6) | 296 (51.3) |
| Female | 4315 (53.0) | 1104 (48.6) | 809 (56.6) | 361 (49.7) | 1244 (58.9) | 317 (54.9) |
| Mean time since T2D diagnosis, yrs. (SD) | 11.5 (6.1) | 8.9 (4.1) | 10.9 (4.4) | 10.3 (4.8) | 15.4 (6.2) | 17.2 (7.9) |
| Duration of T2D | ||||||
| ≤ 10 years | 4243 (52.1) | 1659 (73.1) | 738 (51.6) | 432 (59.5) | 466 (22.1) | 119 (20.6) |
| 10–15 years | 1976 (24.3) | 529 (18.9) | 456 (31.9) | 193 (26.6) | 645 (30.5) | 132 (22.9) |
| > 15 years | 1924 (23.6) | 183 (5.1) | 236 (16.5) | 101 (13.9) | 1001 (47.4) | 326 (56.5) |
| Concordant diseases only | 2880 (35.4) | 722 (31.8) | 511 (35.7) | 276 (38.0) | 861 (40.8) | 215 (37.3) |
| Discordant diseases only | 787 (9.7) | 235 (10.4) | 151 (10.6) | 59 (8.1) | 159 (7.5) | 56 (9.7) |
| Both concordant and discordant diseases | 2005 (24.6) | 412 (18.1) | 291 (20.4) | 169 (23.3) | 630 (29.8) | 212 (37.3) |
| Without concordant or discordant diseases | 2471 (30.3) | 902 (39.7) | 477 (33.4) | 222 (30.6) | 462 (21.9) | 94 (16.3) |
| Good glycaemic control (< 53 mmol/mol) in 2016 | 5636 (69.2) | 2133 (93.9) | 964 (67.4) | 608 (83.8) | 709 (33.6) | 224 (38.8) |
| Died during 2017 | 391 (4.8) | 62 (2.7) | 36 (2.5) | 53 (7.3) | 102 (4.8) | 70 (12.1) |
| Died during the follow-up | 474 (5.8) | 77 (3.4) | 44 (3.1) | 58 (8.0) | 123 (5.8) | 84 (14.6) |
Abbreviations: OAD oral antidiabetic drug, T2D type 2 diabetes
†Concordant diseases: hypertension, coronary heart disease, atrial fibrillation, heart failure, peripheral arterial diseases, stroke (incl. SAH), chronic kidney disease, neuropathies, blindness, or diabetes complications (E11.2-E11.8 sublevels)
‡Discordant diseases: cancers, asthma, gout, glaucoma, depression, dementia, mental diseases, rheumatoid and other arthritis, osteoporosis, neuromuscular diseases, or liver diseases excl. cancers
Note: 1027 patients did not use any diabetes medication in 2016